Patient-Reported Health-Related Quality of Life Impact and Symptom Severity in Patients with Lyme Borreliosis in the Burden of Lyme Disease (BOLD) Study
Pathogens · 2026
DOI: 10.3390/pathogens15070701 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathogens, 2026. Verfasst von Holly Yu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Pfizer Inc., HTA Value and Evidence, Collegeville, PA 19426, USA. Hauptthemen laut MEDLINE: Lyme Disease, Quality of Life. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer (USA), Valneva (Austria), Valneva and Pfizer.
Abstract (Originalsprache)
Lyme borreliosis (LB) can manifest as a localized infection or, if left untreated, disseminated disease. This analysis used Patient-Reported Outcome tools to assess general health, fatigue, pain, and cognitive function in patients with localized or disseminated LB, compared with age- and site-matched controls without LB. All participants were enrolled in the Burden of Lyme Disease (BOLD) study; LB cases were assessed at 3 time points: the enrollment visit, and two follow-up visits conducted within 10 months of enrollment. Controls were evaluated at 2 time points: the enrollment contact and a follow-up contact 16–18 months post-enrollment. Symptom severity and general health quality between groups were compared using two-tailed Student’s t-tests and multivariate regression analyses. Disseminated LB cases reported greater fatigue and pain than localized LB (disseminated LB fatigue scores: 4.1, 3.7, and 3.5 at Visits 1, 2, and 3, respectively vs. localized LB: 2.9, 3.0, and 2.9; disseminated LB pain scores: 2.5, 1.6, and 1.3 vs. localized LB: 0.9, 0.6, and 0.8) and controls (fatigue score: 3.2; pain score: 1.0). Disseminated LB was also associated with reduced health-related quality of life. The results of this study indicate that health-related quality of life may vary by disease stage and that patients with disseminated disease showed persistent impairment during the acute phase and at 10-month follow-up.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pfizer Inc., HTA Value and Evidence, Collegeville, PA 19426, USA.
- Pfizer Inc., HTA Value and Evidence, New York, NY 10001, USA.
- Pfizer Research & Development, Tadworth, Surrey KT20 7NS, UK.
- Pfizer Research & Development/Pfizer Corporation Austria GmbH, 1210 Vienna, Austria.
- Pfizer Inc., Evidence Generation Statistics, Cambridge, MA 02139, USA.
- Pfizer Healthcare Ireland Unlimited Company, The Watermarque Building, Ringsend Road, Dublin 4, D04 K7N3 Dublin, Ireland.
ORCID-Profile: Holly Yu, Amanda R Mercadante, Alexandra Loew-Baselli, Johan S Berglund, Anna Moniuszko-Malinowska, Franc Strle
Förderung
- Pfizer (USA)
- Valneva (Austria)
- Valneva and Pfizer
Zitieren
APA
Yu, H., Mercadante, A. R., Halsby, K., Loew-Baselli, A., Tan, Y., Edwards, J., Angulo, F. J., Begier, E., Dzingina, M., Berglund, J. S., Moniuszko-Malinowska, A., Strle, F., Stark, J. H., & On Behalf Of The Bold Study Group (2026). Patient-Reported Health-Related Quality of Life Impact and Symptom Severity in Patients with Lyme Borreliosis in the Burden of Lyme Disease (BOLD) Study. Pathogens. https://doi.org/10.3390/pathogens15070701
Vancouver
Yu H, Mercadante AR, Halsby K, Loew-Baselli A, Tan Y, Edwards J, et al. Patient-Reported Health-Related Quality of Life Impact and Symptom Severity in Patients with Lyme Borreliosis in the Burden of Lyme Disease (BOLD) Study. Pathogens. 2026. doi:10.3390/pathogens15070701
BibTeX
@article{Yu2026,
author = {Yu, Holly and Mercadante, Amanda R and Halsby, Kate and Loew-Baselli, Alexandra and Tan, Ye and Edwards, Juanita and Angulo, Frederick J and Begier, Elizabeth and Dzingina, Mendwas and Berglund, Johan S and Moniuszko-Malinowska, Anna and Strle, Franc and Stark, James H and On Behalf Of The Bold Study Group},
title = {Patient-Reported Health-Related Quality of Life Impact and Symptom Severity in Patients with Lyme Borreliosis in the Burden of Lyme Disease (BOLD) Study},
journal = {Pathogens},
year = {2026},
doi = {10.3390/pathogens15070701}
}
EUVIMED